Oxford. The first Briton in England was vaccinated with the domestic vaccine from the University of Oxford and the pharmaceutical company AstraZeneca. Britain`s NHS health service has announced that dialysis patient Brian Pinker of Oxford, 82, received the first protective spades on Monday morning at the local university hospital. From 2010 to 2018, Ypsomed was the exclusive distributor of the mylife Omnipodpatch pump in Europe. This cooperation could not be extended and ended on 30 June 2018. During the cooperation, Ypsomed had successfully established the therapy with the insulin patch pump in Europe and, in some cases, gained more than 20% market share in its markets. The agreement with Insulet is a recognition of Ypsomed`s performance, which established the entire distribution structure of the Omnipod in Europe. Burgdorf – Ypsomed (SWX: YPSN) has reached an agreement in its legal dispute with Insulet Corp. (NASDAQ: PODD). Insulet acknowledges the contractually agreed fees and compensates Ypsomed for the termination of the cooperation with an additional $36.15 million.
The total compensation thus amounts to USD 41.25 million. At the same time, Insulet dropped its $18.7 million counterclaim. CHF 1.00 per share as an additional dividend contributionYpsomed is constantly working on the strategic development and direction of its portfolio. The agreement for an additional compensation of USD 36.15 million allows Ypsomed to reduce risk, increase cash flow in the current fiscal year and thus contribute to debt reduction. As announced, in line with a sustainable dividend policy for the 2020/21 financial year, a certain remuneration ratio of CHF 1.00 per share will be proposed as an additional dividend contribution. This corresponds to an additional distribution of CHF 12.6 million. Simon Michel, CEO of Ypsomed, says he is satisfied with the agreement reached with Insulet. « I am very pleased to announce COVID-19 today. To get a vaccine, I`m really proud that it was invented in Oxford, » Pinker said, according to the announcement. Uk Health Secretary Matt Hancock has described the start of vaccination with the drug as an « indispensable step » in the fight against the pandemic. « We have always been convinced that our candidacy was justified. Strategically, we were able to adapt quickly to the new situation.
Now we can focus our operational attention on our growth initiatives in the injection and infusion sector, » learn how to effectively manage the market research process to guide your business on the path to success. Britain issued an emergency permit > to preparedness last week. According to the Biontech/Pfizer vaccine, this is the second corona vaccine to be used in the country. Subscribe to our mailing list to receive ad hoc announcements in accordance with Art. 53 LR and other information. Ypsomed Holding AG (YPSN) – Financial and Strategic SWOT Analysis Review – provides you with an in-depth strategic SWOT analysis of the company`s activities and operations. The profile has been compiled by GlobalData to give you a clear and unbiased overview of the company`s key strengths and weaknesses, as well as potential opportunities and threats. The profile helps you formulate strategies that grow your business by allowing you to better understand your partners, customers and competitors. The profile contains important information about the company, including: The big advantage: The Oxford agent can be kept at the temperature of the refrigerator, which greatly simplifies logistics.
Initially, the country will have a good half a million doses, which will be injected into hundreds of hospitals and doctors` offices starting this week. The vaccine is not yet approved in the EU. (dpa) Life SciencesMedical Devices Company Reports Insulet`s outstanding receivables were on the balance sheet at CHF 42.6 million as at 30 September 2020. In the 2020/21 accounts, Ypsomed therefore reports an exceptional exceptional impairment of around CHF 9 million in EBIT, which has no impact on cash flow. For the 2020/21 financial year, Ypsomed continues to expect slight revenue growth and further growth in operating income from its core operating business. .